12 September 2019
- Little Green Pharma has exported a sample of its commercial products to German cannabis distribution and wholesaler Cansativa GmbH for product testing.
– Cansativa, a GDP-certified pharmaceutical wholesaler operating its own distribution and fulfillment center, is one of the largest importers and distributors of medical cannabis in Germany.
- On completion of product testing the parties intend to finalise the supplier qualification for the European market and necessary compliance requirements.
- Germany is one of the fastest growing markets for medicinal cannabis in Europe since its legalisation in 2017, however all products sold are imported.
- Little Green Pharma was the first and is currently the only, Australian medicinal cannabis company producing locally grown and GMP-manufactured cannabis products for patients.
Western Australian based company Little Green Pharma (LGP), producer of Australia’s first locally grown medicinal cannabis product, has reached a significant milestone in the development of the Australian medicinal cannabis industry by becoming the first Australian company to export a locally grown medicinal cannabis product to Germany.
Having its export licence approved in January 2019, LGP – which leads Australia’s medicinal cannabis industry in the production of medicinal cannabis oil products – has now entered the highly lucrative German market by supplying samples of its commercial products (10:10 LGP Classic and 20:5 LGP classic) to German cannabis distribution and wholesaler Cansativa GmbH (Cansativa) for product testing.
Once product testing by Cansativa in Germany successfully concludes LGP products conform to their label, finalisation of the vendor qualification by Cansativa will take place ensuring compliance with the European regulatory requirements.
Commenting on the achievement of the export milestone Little Green Pharma Managing Director, Fleta Solomon, said, “being Australia’s first local producer of medicinal cannabis to have its products reach European soil is a major milestone in the company’s short history.
“This partnership with Cansativa also highlights that our goal of bringing high-quality, cost-competitive Australian-produced medicinal cannabis to patients around the world has become a reality.
“We are thrilled to be working with a company of Cansativa’s standing, with this partnership just the beginning in LGP achieving its global export goal.”
Germany has become one of the fastest growing markets for medicinal cannabis in Europe since its legalisation in 2017. However, domestic cultivation has lagged due to delays in the tendering process which has resulted in product having to be imported in order to meet the increased demand and undersupply of medicinal cannabis to patients.
Frankfurt-based, GDP-certified pharmaceutical wholesaler Cansativa is seeking to avoid supply bottlenecks becoming one of the largest importers and distributors of medicinal cannabis in Germany.
On the partnership with Little Green Pharma, Cansativa Co-Founder and Co-Managing Director, Benedikt Sons, said, “This partnership underlines Cansativa’s aspiration to provide security of supply in the German market and is an important step for commercialising Australian cannabis in Europe.
“LGP will help us to tackle the growing supply problems in the German market and secure the amount of deliveries necessary to meet the increasing demands by patients. This agreement is an important step in ensuring security of supply for patients in Germany.
“Cansativa has aggregated a lot of know-how over the last year regarding process reliability, dealing with authorities, market structure, competition, and the necessary legal expertise. With the Australian import, we underscore our ambition to provide security of supply through global sourcing”.
For interviews, export updates, clinical study protocols and patient case studies please contact:
David Tasker Chapter One Advisors
M: +61 433 112 936